In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate

Journal of Pharmaceutical Sciences

Volumn 96, Issue 10, 2007, Pages 2622-2631

  Hui, Xiaoying ^a   Baker, Stephen J ^b   Wester, Ronald C ^a   Barbadillo, Sherry ^a   Cashmore, Anne K ^a   Sanders, Virginia ^b   Hold, Karin M ^b   Akama, Tsutomu ^b   Zhang, Yong Kang ^b   Plattner, Jacob J ^b   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

Absorption; AN2690; Diffusion; Drug effects; Log p; Nail penetration; Onychomycosis; Solubility

Indexed keywords

AN 2690; ANTIFUNGAL AGENT; CICLOPIROX; CICLOPIROXOLAMINE; OXABOROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; FINGER NAIL; HUMAN; HUMAN TISSUE; NAIL PLATE; ONYCHOMYCOSIS;

EID: 35348994986     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20901     Document Type: Article

References (24)

1. Faergemann J, Baran R. 2003. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 149:1-4.
2. Arrese JE, Piérard GE. 2003. Treatment failures and relapses in onychomycosis: A stubborn clinical problem. Dermatology 207:255-260.
3. Elewski B, Charif MA. 1997. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 133:1172-1173.
4. Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, Summerbel RC. 2000. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: A multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 43:244-248.
5. Summerbel RC, Kane J, Krajden S. 1989. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 32:609-619.
6. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel r, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-de-leon GF, Ghannoum A, Warner J, Isham N, Elewski B. 2000. A large scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution and antifungal susceptibility patterns. J Am Acad Dermatol 43:641-648.
7. Adiguna MS. 2000. New therapies for onychomycosis. Med Prog May: 17-22.
8. Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MRK, Sanders V, Plattner JJ. 2006. Discovery of a new boron-containing anti-fungal agent, 5-fluoro-1,3-dihydro1-hydroxy-,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 49: 4447-4450.
9. Hui X, Shainhouse Z, Tanojo H, Anigbogu A, Markus GE, Maibach HI, Wester RC. 2002. Enhanced human nail drug delivery: Nail inner drug content assayed by new unique method. J Pharm Sci 91:189-195.
10. Hui X, Chan TCK, Barbadillo S, Lee C, Maibach HI, Wester RC. 2003. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 92:142-148.
11. Myoung Y, Choi H. 2003. Permeation of ciclopirox across porcine hoof membrane: Effect of pressure sensitive adhesives and vehicles. Eur J Pharm Sci 20:319-325.
12. Haneke E. 1991. Fungal infections of the nail. Semin Dermatol 10:41-53.
13. Gupchup GV, Zatz JL. 1999. Structural characteristics and permeability properties of the human nail: A review. J Cosmet Sci 50:363-385.
14. Walters KA, Flynn GL. Permeability characteristics of the human nail plate. Int J Cosmet Sci 5:231-246.
15. Mertin D, Lippold BC. 1997. In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: Influence of the partition coefficient octanol/water and the water solubility of drugs on their permeability and maximum flux. J Pharm Pharmacol 49:30-34.
16. Walters KA, Flynn GL, Marvel JR. 1983. Physicochemical chemical characterization of the human nail: Permeation pattern for water and the homologous alcohols and difference with respect to the stratum corneum. J Pharm Pharmacol 35:28-33.
17. Palmeri A, Pichini S, Pacifici R, Zuccaro P, Lopex A. 2000. Drugs in nails: Physiology, pharmacokinetics and forensic toxicology. Clin Pharmacokinet 38:95-110.
18. Baden HP, Goldsmith LA, Fleming B. 1973. A comparative study of the physicochemical properties of human keratinized tissues. Biochim Biophys Acta 322:269-278.
19. Murdan S. 2002. Drug delivery to the nail following topical application. Int J Pharmaceut 236:1-26.
20. Bohn M, Kraemer K. 2000. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc 90:491-494.
21. Gupta AK, Baran R. 2000. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Derm 43:s96-s102.
22. Hui X, Wester RC, Barbadillo S, Lee C, Patel B, Wortzmman M, Gans EH, Maibach HI. 2004. Ciclopirox delivery into the human nail plate. J Pharm Sci 93:2545-2548.
23. Hui X, Wester RC, Barbadillo S, Maibach HI. 2005. Nail penetration: Enhancement of topical delivery of antifungal drugs by chemical modification of the human nail. In: Baran R, Maibach HI, editors. Textbook of cosmetic dermatology, 3rd edition. London and New Yew York: Taylor & Francis. pp 57-63.
24. Alley MRK, Baker SJ, Beutner KR, Plattner JJ. Recent progress on the therapy of onychomycosis. Expert Opin Investig Drug 6:157-167.